AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05799755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
Study NCT05662215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-3828136
Description: CK-3828136
Study NCT05662215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CK-3828136
Description: Placebo for CK-3828136
Study NCT06647836 — intervention group
Intervention type: OTHER
Intervention: Efficacy observation
Description: Observation about the efficacy of sq-NSCLC patients receiving immunotherapy combined with or without chemotherapy as first-line treatment.
Study NCT06372470 — intervention group
Intervention type: OTHER
Intervention: Zestril
Description: N/A, this is an observational study.
Study NCT05326529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Based Cardiac Rehabilitation Exercise Classes
Description: Participants will attend 8 Hospital based CR exercise sessions. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
Study NCT05326529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital Based Cardiac Rehabilitation Exercise Classes
Description: Participants will attend 8 Hospital based CR exercise sessions. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
Study NCT06061497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdomino-diaphragmatic breathing
Description: Breathing should be done twice a day for 10 minutes.
Study NCT06061497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Health education Review of inhaler technique Check adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity
Study NCT06061497 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Health education Review of inhaler technique Check adherence to treatment; Presence of comorbidities; Smoking; Other environmental factors; Promotion of physical activity
Study NCT05607095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel (LN-144/LN-145)
Description: Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.
Study NCT06417554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102
Description: SHR-A2102
Study NCT06417554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102 ; Adebrelimab injection
Description: SHR-A2102 + Adebrelimab injection
Study NCT04705909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 2 mg oral tablets daily will be given to the patients concomitantly with the intended chemotherapy protocol for the treatment period prior to surgery.
Study NCT04705909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients in this group will receive placebo tablets concomitantly with the intended chemotherapy for the treatment period prior to surgery.
Study NCT05326529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based Cardiac Rehabilitation Exercise Sessions
Description: Participants will complete 8 weeks of Web-based CR exercise sessions using the MyHeart app. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
Study NCT05086133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: transcranial magnetic stimulation with continuous theta burst pattern, 90% RMT, 50Hz within train and 5Hz train for 200 train and 40 second in total.
Study NCT05086133 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: TMS coil vertical to the brain surface, with same protocol as cTBS
Study NCT05381974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Open-Label
Study NCT05916651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning to Offset Stress (LOS) (in Dutch: Leren Omgaan met Stress) training
Description: The investigational treatment is the LOS training, which is an adaptation of two previously validated mindfulness-based programs: Mindfulness-Based Cognitive Therapy (MBCT) developed by Segal, Williams, and Teasdale (2002) and the Mindful2Work (M2W) program developed by de Bruin, Formsma, and Bögels (2018). The M2W program combines mindful physical activity, yoga, and mindfulness meditation to target stress symptoms and burn-out in adults. The LOS training was adapted from these programs to meet the needs of youth with internalizing problems. The training consists of 8 weekly 2-hour sessions that each comprise three elements: mindful physical activity (15-20 minutes), yoga (15-20 minutes), and mindfulness meditation exercises (80-90 minutes). In addition to attending group sessions, participants are invited to practice at home on a daily basis. Home practice consists of daily mindfulness practices comprising mindfulness exercises, yoga and mindful physical activity.
Study NCT05916651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Youth who seek help for internalizing problems from a primary mental health practitioner, including student psychologists or mental health nurse practioners, but do not (yet) meet criteria for (major) mental illness are typically offered supportive counselling, aimed primarily at helping people feel understood and supported. Supportive counselling may also include instructions on behavioral activation, particularly when individuals report reduced activity and behavioral avoidance including social withdrawal. In addition, mental health practitioners commonly employ a watchful waiting policy for people with symptoms in the milder range, where they check-in with clients on a regular basis and refer for more intensive treatment if and when symptoms worsen.
Study NCT05916651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care as usual
Description: Youth who seek help for internalizing problems from a primary mental health practitioner, including student psychologists or mental health nurse practioners, but do not (yet) meet criteria for (major) mental illness are typically offered supportive counselling, aimed primarily at helping people feel understood and supported. Supportive counselling may also include instructions on behavioral activation, particularly when individuals report reduced activity and behavioral avoidance including social withdrawal. In addition, mental health practitioners commonly employ a watchful waiting policy for people with symptoms in the milder range, where they check-in with clients on a regular basis and refer for more intensive treatment if and when symptoms worsen.
Study NCT04909801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept SC (125 mg) once weekly
Study NCT04909801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab SC (40 mg) once every 2 weeks
Study NCT04909801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)
Study NCT04998357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endovascular autologous mitochondrial transplantation
Description: During standard-of-care endovascular reperfusion procedure, subjects will have autologous mitochondria infused via microcatheter into ischemic brain.
Study NCT06058650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Breast
Description: Undergo biopsy of breast
Study NCT06058650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Utilization of the Stereo Navigator accessory
Study NCT06058650 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scintimammography
Description: Undergo MBI
Study NCT06058650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sestamibi
Description: Given IV
Study NCT06443268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaire, hair samples, blood samples, clinical exam
Description: The following parameters will be sequentially assessed in caregivers and patients (baseline, at 3 months and at 12 months): 1) quality of life / functioning will be determined through questionnaires (SF-36, EQ-5DL, ECOG (Eastern Cooperative Oncology Group) / Karnofsky, Barthel Index, ICIQ) 2) stress levels \& anxiety levels, caregiver burden will be assessed by the following questionnaires: Distress Thermometer, SBQ-G, GAD-7, PHQ-9, PSS-10, ZBI, PAC. Cortisol will be measured in hair to indicate stress within the past 3 months \[18\]. Fasting glucose, lipid profiles and HbA1c along with blood count, sodium, potassium, creatinine, TSH (thyroid-stimulating hormone) will be measured in routine blood samples from patients at the time of clinical checkups. Blood pressure, pulse and BMI will be determined during clinical visit in patients and additionally in caregivers.
Study NCT04453631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: 26 transcranial direct current stimulation sessions, each lasting 20 minutes, with a current intensity of 2 mA, the cathode placed over the right dorsolateral prefrontal cortex and the anode placed over the left deltoid muscle.
Study NCT04453631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: 26 transcranial direct current stimulation sessions, each lasting 20 minutes, with a current intensity of 2 mA, the cathode placed over the right dorsolateral prefrontal cortex and the anode placed over the left deltoid muscle.
Study NCT04453631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS
Description: tDCS is controlled in this intervention: sham mode.
Study NCT04453631 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: tDCS is controlled in this intervention: sham mode.
Study NCT04453631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-UP
Description: 15 psychotherapy sessions (1/week) following the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders developed by Barlow et al. 2018.
Study NCT04453631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-UP
Description: 15 psychotherapy sessions (1/week) following the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders developed by Barlow et al. 2018.
Study NCT04453631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: To control for the cognitive-behavioral intervention we will use psychoeducation materials.
Study NCT04453631 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: To control for the cognitive-behavioral intervention we will use psychoeducation materials.
Study NCT06429254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Life Scale will be administered as pre-tests to the EFT group. After the pre-tests, the first EFT session will be conducted. A second EFT session will take place 30 days later, followed by post-tests. During this period, affirmations will be provided as needed based on individual difficulties, perspectives, support systems, past traumas, and emotional blockages experienced by the woman. Each session is planned to last approximately 45 minutes to 1 hour.
Study NCT05053620 — intervention group
Intervention type: DEVICE
Intervention: Calculation of the arcuate intrasomal incisions
Description: All patients participating in the study will undergo femtosecond laser treatment for the correction of astigmatism through arcuate intrastromal incisions with the Catalys laser (Johnson \& Johnson, USA, CE marked). The calculation of intrastromal arcuate incisions will be carried out using the following nomogram indicated on the laser: 9.0 mm optical zone and symmetrical incisions of 50 degrees for 0.50D, 55 degrees for 0.75D, 60 degrees for 1.00D and 65 degrees for 1.25D of corneal astigmatism. After the incisions, conventional cataract surgery will be performed using the Centurion phacoemulsifier equipment (Alcon, USA, with CE marking) in the ZCB00 monofocal intraocular lens (IOL) implant (Johnson \& Johnson, USA, with CE marking). All patients will be treated according to standard clinical practice.
Study NCT05011851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
Study NCT04949373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy (HILT)
Description: High intensity laser therapy-Patients will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program will be performed on each session.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks.
Study NCT04949373 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High-intensity laser therapy (sham HILT)
Description: Sham high intensity laser therapy-Participants will receive pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions.~Other: Tendon and nerve gliding exercises will be performed three times a day with 10 repetitions each time for 3 weeks. Exercises will be performed by a trained physiotherapist.~Other: Rest splint(at night) Participants will be splinted in neutral position with standard cotton-polyester splints.The patients will be encouraged to use the splints during nighttime for 12 weeks.
Study NCT06498765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacifier Use
Description: The newborns in the experimental group were given a pacifier, unlike the control group. The newborns were placed in a phototherapy incubator and each time they were placed in a phototherapy incubator, the newborns were given a pacifier for an average of 5 minutes. The researcher encouraged the babies to take the pacifier.
Study NCT05491148 — intervention group
Intervention type: OTHER
Intervention: work conditions
Description: an increased degree of responsibility for the life of newborns, high psycho-emotional stress, intellectual stress, an irrational work and rest regime, in connection with the COVID-19 pandemic, also using personal protective equipment against biological factors
Study NCT05478655 — intervention group
Intervention type: OTHER
Intervention: visual analog scale
Description: VAS was studied: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital and further 1, 3, 6, 12 months after the injury; 5) at the rehabilitation stage. Intervals between analgesia were also studied.
Study NCT06102044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Supplements
Description: Dispersible zinc sulfate tablets
Study NCT06102044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplements
Description: Dispersible placebo tablets
Study NCT06024564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonu Acoustic Resonance Therapy
Description: Participants will receive Sonu treatment twice a day for 90 days
Study NCT05575076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam
Description: simufilam 100 mg oral tablet, twice daily
Study NCT06205667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer Guided Arthrocentesis
Description: patients are going to be injected intra-articular within the superior joint space of the affected TMJ through custom guided template planned in a manner inspired by earphone design to get support from the tragus.
Study NCT06205667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Arthrocentesis
Description: patients are going to be injected intra-articular within the superior joint space of the affected TMJ using conventional method anatomical landmark determination
Study NCT06389838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kranus Mictera
Description: An app-based digital therapy program aimed at multimodal self-treatment for incontinence. The app is certified class I medical device (MDR).
Study NCT06360939 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Delivery of 25Gy in a single dose fraction to target area within 6 weeks of randomization
Study NCT06360939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CA
Description: CA (endocardial and/or epicardial at operator discretion) within 6 weeks of randomization.
Study NCT05152680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-NV-5138
Description: Single dose, given as oral solution, 1600 mg
Study NCT06398327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PULPOTOMY TREATMENT
Description: During pulpotomy treatment, a bleeding sample was taken from the pulp and levels of presepsin, IL-6 and IL-8, which are important inflammation markers, were determined. During the treatment, MTA, Neo MTA, Biodentine and ZOE groups were randomly selected and the remaining pulp tissue was covered. After pulpotomy treatment, the teeth were followed for one year. Treatment success was evaluated according to the material used in teeth with high levels of inflammation at the beginning.
Study NCT02866565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adipose-derived regenerative cells (ADRCs)
Description: injection of the experimental treatment
Study NCT05060328 — intervention group
Intervention type: OTHER
Intervention: Medical Device Usage and Evaluation
Description: Use Google Translate Conversation Mode translation application.
Study NCT05060328 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT05861336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan will be administered at the dose of 25 mg PO qd starting on Cycle 1 Day 1. If this dose will be tolerated during week 1, escalation to 50 mg PO qd at Cycle 1 Day 8
Study NCT05861336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 28 days
Study NCT05861336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: nab-paclitaxel 125 mg/m2 on days 1, 8, and 15
Study NCT05861336 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 7 consecutive fractions for a total dose of 35-42 Gy
Study NCT05112965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
Study NCT05112965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered as directed per the parent study.
Study NCT04222998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based growth charts
Description: The growth chart contains simple information of nutritious food, health, and sanitation information at the top and height chart is located at the bottom where caregivers can measure their child's linear growth. Growth charts will be installed in intervention group homes just after the baseline survey.
Study NCT04222998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home visits for baseline surveys
Description: Households will be visited for baseline surveys.
Study NCT04222998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visits for baseline surveys
Description: Households will be visited for baseline surveys.
Study NCT05112965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered as directed per the parent study.
Study NCT06388785 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT06546566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Game-Based Breathing Exercises
Description: The video game-based breathing exercises program will consist of 5 breathing games included in the BreathingLabs game kit and each game will be performed in 2 sets of 10 repetitions. The program will last for 8 weeks, 5 days a week, 30 minutes a day.